BCR-Abl-targeting TKIs inhibit the activity of the BCR-Abl fusion protein, which is characteristic of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [63]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.